VRTX
VERTEX PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 1 ▼ 1 insider sell $439.3K at $449.17
- May 1 to May 4 ▼ 2 days of insider sells: $604.0K by 2 insiders, avg $424.73
- May 12 to May 15 ▼ 2 days of insider sells: $3.8M by 2 insiders, avg $450.57
- May 29 to Jun 5 ▼ 3 days of insider sells: $2.0M by 2 insiders, avg $448.16
- Jun 15 to Jun 18 ▼ 2 days of insider sells: $2.3M by 1 insider, avg $452.44
- Jun 26 to Jul 2 ▼ 3 days of insider sells: $2.3M by 4 insiders, avg $513.12
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 7 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Nov 9
- Oct 14 Trial readout: Results Pending: Povetacicept (Phase 2), Completed 63d ago
- Oct 14 to Oct 19 2 court rulings: VERTEX, INC. v. AVALARA, INC. et al; Vertex Towers, LLC v. Town of Franklin
- Nov 2 ▲ Vertex reported Q3 2026 total revenue of $3.44 billion, a 12% increa…
- Nov 6 ▼ 1 insider sell $6.3M at $531.53
- Nov 12 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
7 insiders sold $17.8M. Excludes 1 subscriber-only trade.
- InstitutionsMIXED
Q3 2026: 52 added (4 new), 35 trimmed or exited. Largest new: Migdal Insurance & Financial Holdings $47.6M, Picton Mahoney Asset Management $14.7M.
- AnalystsBULLISH
32 of 39 rate it Buy or better. Median target $609.50 (+14%).
- Short sellersSTEADY
Short interest +12.9% to 4.81M shares. 3.4 days to cover, ≈1.9% of shares.
- TrendUPTREND
2% above its 50-day average.
- SocialQUIET
Crowd 67° (warm) this week from 2 mentions: 2 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | ADD | $2.4B |
| Clearbridge Investments, LLC | TRIM | $885.9M |
| Assenagon Asset Management S.A. | ADD | $637.5M |
| Neuberger Berman Group LLC | ADD | $429.1M |
| FIRST TRUST ADVISORS LP | DOUBLED | $366.8M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $306.3M |
| BARCLAYS PLC | TRIM | $274.3M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $239.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
39 analystsPrice is inside the target range. Median implies +14%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Barclays MAINTAIN | Overweight |
| Nov 3, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 3, 2026 | Goldman Sachs MAINTAIN | Buy |
| Nov 3, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 3, 2026 | Scotiabank MAINTAIN | Sector Outperform |
| Nov 3, 2026 | UBS MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
Kewalramani Reshma CEO & President Nov 6, 2026 | SELL | $6.3M |
Brennan Daniel J. Director Oct 20, 2026 | AWARD | $400.3K |
SACHS BRUCE I Director Oct 15, 2026 | AWARD | $47.5K |
Garber Alan M Director Oct 15, 2026 | AWARD | $15.0K |
van Grunsven Jasper EVP, CP and NPPO Sep 8, 2026 | AWARD | 8,682 sh |
Ambrose Kristen SVP & Chief Accounting Officer Aug 28, 2026 | AWARD | 5,000 sh |
SACHS BRUCE I Director Aug 27, 2026 | GIFT | 6,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
21 filings · 3 bullish · 1 bearish · 17 neutral- NEUTRAL CLUSTERNov 16, 2026
Two top executives at Vertex, including the CEO and EVP/CO/FO, sold a combined $14.68M in open-market sales under 10b5-1 plans over a 7-day window. The total represents about 0.01% of market cap, which is trivial relative to the company's $137.6B valuation, and the sales are pre-planned, reducing…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 16, 2026
Vertex Pharmaceuticals director Nancy Thornberry filed a Form 144 notice of intent to sell 1,000…
The filing is a standard advance notice for a small insider sale by a director. No material impact on the stock is expected. Monitor for any subsequent Form 4 filings to confirm execution.
- NEUTRAL 144Nov 16, 2026
Director Sangeeta Bhatia filed a Form 144 notice of intent to sell 271 shares of Vertex…
The sale amount is negligible and routine for director compensation vesting. No material impact on stock expected. Monitor for any larger insider sales or changes in insider filing patterns.
- NEUTRAL SC 13G/ANov 13, 2026
Capital Research Global Investors filed an amended Schedule 13G disclosing a 7.0% passive stake in…
The incremental share increase is routine portfolio rebalancing by a large passive manager. No change in investment thesis; monitor next 13F for broader institutional positioning trends.
All VRTX filing & press-release reports (21)
- CLUSTER reportNov 16, 2026
- 144 reportNov 16, 2026
- 144 reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- 144 reportNov 12, 2026
- 144 reportNov 6, 2026
- 8-K reportNov 2, 2026
- 3 reportOct 22, 2026
- 8-K reportOct 20, 2026
- INST-CLUSTER reportOct 16, 2026
- CLUSTER reportJul 7, 2026
- 8-K reportJul 6, 2026
- CLUSTER reportJul 6, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMar 11, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026